TheranosticTrials.org

Clinical Trial · NCT07052760

Imaging of Solid Tumors Using DLL3 SPECT

Overview

This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors. 111In-ABD147 is a high affinity Delta-like ligand 3 (DLL3) antigen binding domain fused to an engineered humanized Fc to create an antibody (VHH-Fc) that is bio-conjugated with a DOTA linker-chelator to a 111In radiometal. DLL3 is expressed on a variety of tumors, particularly those with neuroendocrine features.

Sponsor

University of California, San Francisco

Phase

Early Phase 1

Contacts

Thomas A Hope, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07052760

Drug / Compound

ABD147

Isotope(s):
Target(s):
  • DLL3
Ligand Class: Small Proteins and Antibody Fragments
Chelator: DOTA

Eligibility

Inclusion

  • Cohort 1 (n=15): Histologically confirmed prostate cancer, with castration resistant disease per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.
  • Histopathologically confirmed solid tumors in one of the following cohorts:
  • Metastatic disease present on conventional imaging defined as having Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease or multiple bone metastases.
  • Cohort 2 (n=15): Histologically confirmed high grade neuroendocrine tumor, with a Ki-67 over 20.
  • Cohort 3 (n=15): Agnostic to tumor type.

Exclusion

Exclusion criteria not yet provided.